At the Breast Cancer Comprehensive Center (BCCC), National Cancer Institute, Cairo University (Cairo, Egypt), the standard pathway for HER2-positive early breast cancer includes neoadjuvant chemotherapy plus dual anti-HER2 therapy (trastuzumab + pertuzumab), definitive surgery, and adjuvant systemic therapy and/or radiotherapy as indicated. Here, ERBB2 is linked to breast carcinoma.